Richard William Scalzo Sells 1,343 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) SVP Richard William Scalzo sold 1,343 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total value of $15,283.34. Following the sale, the senior vice president now owns 122,330 shares in the company, valued at $1,392,115.40. The trade was a 1.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $12.05 on Friday. Dyne Therapeutics, Inc. has a 1 year low of $11.18 and a 1 year high of $47.45. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -3.38 and a beta of 1.11. The firm’s 50-day moving average is $14.83 and its two-hundred day moving average is $25.63.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on DYN shares. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $50.00 price objective for the company. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Friday, February 28th. Finally, Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.85.

Get Our Latest Research Report on Dyne Therapeutics

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $34,000. Point72 DIFC Ltd bought a new position in Dyne Therapeutics in the third quarter worth about $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at about $50,000. Finally, KBC Group NV grew its position in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Featured Articles

Insider Buying and Selling by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.